ClinicalTrials.gg
RecruitingNCT07454226Updated May 13, 2026

ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL

An interventional study of Olverembatinib and Gecacitinib in Ph-Like and Acute Lymphoblastic Leukemia, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 1 site in China. Open to participants aged 14 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
92
Allocation
Non-randomized
Ages
14 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Institute of Hematology & Blood Diseases Hospital, China — 21 open to participants now, 22 under way, 4 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · Institute of Hematology & Blood Diseases Hospital, China.

Planned enrollment
6th of 26
92 · median 43
Started
2026
with 6 others
No phase
5 of 28
5 open now
Primary completion
2028-03
later than 12 of 21 live
Registered
23rd of 28
by date

Among the 28 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Institute of Hematology & Blood Diseases Hospital, China, this one is the 6th largest by planned enrollment of the 26 interventional ones that give a count, is one of 7 that started in 2026, is one of 5 with no phase, reaches primary completion later than 12 of the 21 other live ones, and was the 23rd registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

21 of the 28 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Institute of Hematology & Blood Diseases Hospital, China are open now, in 2 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 21 open studies →

Where they have run

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 14 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Institute of Hematology & Blood Diseases Hospital, China, or all of them as a file.
02

Study summary

This open-label, non-randomized, phase II exploratory study aims to evaluate the efficacy and safety of combining pathway-specific tyrosine kinase inhibitors with chemotherapy and venetoclax in patients with newly diagnosed Ph-like acute lymphoblastic leukemia (ALL). Patients are stratified by genetic alteration: those with ABL class fusions (ABL1, ABL2, PDGFRA, PDGFRB) receive olverembatinib, while those with JAK pathway alterations (CRLF2 rearrangement, JAK mutation/fusion, EPOR fusion, SH2B3 deletion, IL7R mutation) receive Gecacitinib. Both groups undergo sequential induction, consolidation, intensification, and maintenance therapy as per protocol.

The primary endpoint is the rate of flow cytometry minimal residual disease (MRD)-negative complete remission (CR MRD-) at 3 months after induction therapy. Secondary endpoints include overall complete remission rate, NGS MRD-negative CR rate at 3 months, overall survival (OS), disease-free survival (DFS), relapse-free survival (RFS), cumulative incidence of relapse, and 60-day mortality.

03

Conditions studied

  • Ph-Like
  • Acute Lymphoblastic Leukemia
04

Who can participate

Ages eligible
14 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥14 years and ≤60 years, regardless of gender
  • performance status score ≤2
  • Male and female participants of agree to and adopt effective measures
  • Criteria for major organ function assessment: total \<1.5 × (ULN), (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN; serum creatinine \<2 × ULN; myocardial enzymes \<2 × ULN; serum amylase ≤1.5 × ULN; (LVEF) >45% as shown by cardiac ultrasound

Exclusion criteria

Exclusion Criteria:

  • Pregnant women
  • Severe uncontrolled active infections
  • Mental illnesses that may hinder the completion of treatment or
  • Other conditions deemed unsuitable for this study by the investigator
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
92 participants (estimated)

Study arms

  • Experimental
    ABL pathway group

    Patients with ABL class fusions receive olverembatinib combined with chemotherapy and venetoclax. Induction (VOVP): vincristine days 1,8,15,22; prednisone days 1-28; venetoclax days 1-28; olverembatinib every other day days 1-28. Consolidation (CAMVT): cyclophosphamide day 1; cytarabine days 1,2,8,9; 6-MP days 1-7; olverembatinib every other day days 1-28 for 2 cycles. Subsequent therapy: HD-MTX (days 1,14; olverembatinib withheld); ID-AraC (days 1-3); VPO (vincristine days 1,8; prednisone days 1-14; olverembatinib every other day); repeat HD-MTX; repeat ID-AraC; COAP (cyclophosphamide day 1; vincristine day 1; cytarabine days 1-7; prednisone days 1-7). Maintenance: alternating MM (6-MP/MTX) and VP + venetoclax, with continuous olverembatinib.

    Drug: Olverembatinib · Drug: Venetoclax · Drug: Chemotherapy Regimen · Drug: Blinatumomab · Procedure: CAR-T Cell Therapy · Procedure: Allogeneic HSCT

  • Experimental
    JAK pathway group

    Patients with JAK pathway alterations receive Gecacitinib combined with chemotherapy and venetoclax. Induction (VDCLP+V): vincristine days 1,8,15,22; daunorubicin days 1-3; cyclophosphamide days 1,15; pegaspargase day 5; prednisone days 1-28; venetoclax days 6-14 (may extend to day 21). Consolidation (CAMVT): cyclophosphamide day 1; cytarabine days 1,2,8,9; 6-MP days 1-7; vincristine day 1; ruxolitinib 100 mg twice daily days 1-28 for 2 cycles. Subsequent therapy (ruxolitinib withheld): early intensification (HVL), delayed intensification (VDLD then CAMVL), repeated once. Maintenance: alternating MM and VP + venetoclax, with continuous ruxolitinib.

    Drug: Gecacitinib · Drug: Venetoclax · Drug: Chemotherapy Regimen · Drug: Blinatumomab · Procedure: CAR-T Cell Therapy · Procedure: Allogeneic HSCT

Interventions

  • Third-generation TKI targeting ABL class fusions. 40 mg every other day, continuous throughout all phases except during HD-MTX.

  • DrugJaktinibStudies of JaktinibJaktinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    JAK1/2 inhibitor targeting JAK pathway alterations. 100 mg twice daily during CAMVT consolidation and maintenance.

  • BCL-2 inhibitor. Escalating doses (100→200→400 mg) during induction; 400 mg during maintenance VP cycles.

  • DrugChemotherapy Regimen

    Multi-agent chemotherapy including vincristine, prednisone, daunorubicin, cyclophosphamide, pegaspargase, cytarabine, 6-MP, MTX, and dexamethasone per protocol phases.

  • Optional CD19-directed BiTE antibody. 28-day continuous infusions alternating with chemotherapy.

  • ProcedureCAR-T Cell Therapy

    Optional cellular immunotherapy preceded by fludarabine/cyclophosphamide lymphodepletion.

  • ProcedureAllogeneic HSCT

    Stem cell transplantation for eligible patients in first complete remission.

06

What researchers measure

Primary outcomes

  1. Rate of flow cytometry-minimal residual disease (flow-MRD) negative complete remission at 3 months after treatment initiation

    Time frame: At 3 months after treatment initiation

Secondary outcomes

  1. Complete response (CR) rate

    Time frame: At completion of induction therapy

  2. Rate of next-generation sequencing-MRD (NGS-MRD) negative complete remission at 3 months post-treatment

    Time frame: At 3 months after start of treatment

  3. Overall survival

    Time frame: Up to 5 years

  4. Disease-free survival

    Time frame: Up to 5 years

  5. Relapse-free survival

    Time frame: Up to 5 years

  6. Cumulative incidence of relapse

    Time frame: Up to 5 years

  7. 60-day mortality rate

    Time frame: At 60 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Mar 2028, 21 months later.

Of 207 non-industry interventional studies with no phase under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 66. This study's planned 21 months is below that.

Counting every sponsor, half of 214 studies reached it within 32 months; a quarter within 12 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Mar 6, 2026
StartEst.
May 30, 2026
Primary completionEst.
Mar 1, 2028
CompletionEst.
Mar 1, 2030
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07454226
Responsible party
Sponsor
First posted
Mar 6, 2026
Start date
May 30, 2026 (estimated)
Primary completion
Mar 1, 2028 (estimated)
Completion
Mar 1, 2030 (estimated)
Last update
May 13, 2026

Study contacts

Hui Wei, MD
Contact
weihui@ihcams.ac.cn
13132507161

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion